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Successful treatment of eosinophilic esopha-
gitis with ciclesonide
To the Editor:
Swallowed topical steroids, allergen elimination diets, or both
are the primary treatment for patients with eosinophilic esopha-
gitis (EoE).1 To date, 2 steroid preparations, fluticasone and bude-
sonide, have been shown to offer therapeutic benefit for patients
with EoE.2-4 Clinical experience suggests that some patients are
unresponsive to either of these topical steroids.Whether this is re-
lated to inadequate dosing, improper technique of administration,
low steroid concentrations on the epithelial surface, genetically
determined steroid unresponsiveness, or poor adherence is uncer-
tain, but additional therapeutic options are necessary.
Ciclesonide is a topical steroid of proved benefit in the
treatment of allergic diseases, such as asthma, allergic rhinitis,
and allergic conjunctivitis.5-7 It is a nonhalogenated parent
compound that is converted by epithelial esterases to form the bi-
ologically potent desisobutyryl-ciclesonide (des-CIC). This con-
version facilitates a high concentration of active metabolite at the
mucosal surface.8 In vitro comparisons demonstrate that des-CIC
exhibits a 100-fold greater glucocorticoid receptor binding than
the parent compound ciclesonide. des-CIC possesses a number
of mechanistic properties, one of which is limiting eosinophil mi-
gration.9 Measurements of systemic levels of biologically active
steroid components are less in patients administered ciclesonide
compared with those administered fluticasone or budesonide (in-
haled corticosteroids).10 In vitro animal and human studies com-
paring ciclesonide with alternative inhaled corticosteroids in
asthmatic patients provide evidence that equivalent or lower
doses of ciclesonide result in similar clinical responses. These
studies also indicate that there are fewer systemic steroid effects(osteopenia, adrenal suppression, and oral candidiasis).6,10 In
combination, these features suggest that ciclesonide might be
an attractive therapeutic option for the treatment of EoE. There-
fore we hypothesized that ciclesonide would provide therapeutic
efficacy in the treatment of children with EoE.
As an initial step, we investigated whether esophageal squa-
mous epithelia expressed carboxylesterases known to esterify
ciclesonide. As a part of an institutional review board–approved
protocol, RT-PCR was performed on esophageal mucosal biopsy
samples from children undergoing endoscopy at Children’s
Hospital Colorado who had normal esophageal mucosa, active
EoE, or treated EoE. As seen in Fig 1, all esophageal mucosal
samples expressed carboxylesterases 1 and 2, a finding that sup-
ports the use of ciclesonide in the treatment of EoE. We per-
formed a chart review to identify patients who received
ciclesonide as treatment for EoE in the Gastrointestinal Eosino-
philic Diseases Program at Children’s Hospital Colorado and Na-
tional Jewish Health. The diagnosis of EoE had been made
according to previously established published guidelines.1 Six pa-
tients in our program were treated with ciclesonide, but only the 4
who were treated for at least 2 months and had undergone pre-
treatment and posttreatment biopsies were reviewed. Clinical fea-
tures, including symptoms, doses of medication, endoscopic
appearances, and histopathologic findings, were recorded as
shown in Table I. Patients had received instructions to swallow
2 actuations of the metered-dose inhaler (80 or 160 mg) twice a
daywithout using a spacer, rinsing their mouth, or eating or drink-
ing for 30 minutes afterward.
Indications for using ciclesonide were lack of clinical response
to fluticasone, dietary restrictions, or parental concerns about
systemic steroid exposure. During ciclesonide treatment, there
were no changes in patients’ dietary restrictions, maintenance
medications, or use of oral systemic steroids. Patients were
prescribed ciclesonide at varied times between the summer and
fall seasons (Table I). Environmental allergen sensitization in pa-
tient 1, a 4-year-old boy with eczema, had not been assessed at the
time of treatment. Patients 2, 3, and 4 were sensitized to spring,
fall, and perennial allergens, as determined by means of skin
testing, and patient 4 was receiving maintenance allergen
immunotherapy.
All 4 patients experienced both a clinical and histologic benefit
from the use of swallowed topical ciclesonide. Symptoms
resolved in all patients, and eosinophil numbers decreased
significantly in both proximal biopsy specimens (71 6 25.5 vs
1.75 6 2 eosinophils/high-power field; P 5 .007, before vs after
treatment, respectively) and distal biopsy specimens (76.25 6
33 vs 0.75 6 1.5 eosinophils/high-power field; P 5 .009, before
vs after treatment, respectively). In addition, when present on ini-
tial biopsy specimens, a number of histologic features, including
basal cell hyperplasia, rete peg elongation, spongiosis, and
edema, also decreased after ciclesonide treatment. No side effects
were found, including thrush, acne, hirsutism, increased bruising,
or mood swings, at 2 months after initiation of treatment.
Ciclesonide might have offered clinicopathologic benefit in
children with EoE because of high local des-CIC concentrations.
des-CIC exhibits local anti-inflammatory effects that include
reduction in eosinophil migration, diminished lymphocyte cyto-
kine production, decreased fibroblast eotaxin release, and reduced
smooth muscle actin expression.9 Clinically, ciclesonide pos-
sesses potent actions in asthmatic patients, as evidence by reduced
sputum eosinophils, reduction in exhaled nitric oxide levels, and
FIG 1. Esterase expression in esophageal tissues. Esophageal biopsy specimens were collected from
healthy subjects, patients with active EoE, and patients with treated EoE. cDNA measurements were made
(Applied Biosystems, Foster City, Calif), and quantitative PCRwas completed (Absolute Blue QPCR RoxMix;
Thermo Scientific, Waltham, Mass) by using high-fidelity TaqMan probes (Applied Biosystems). Gene
probe identification numbers Hs00275606 and Hs01077951 were for carboxylesterases 1 (95 bp) and 2 (93
bp), respectively. Products were visualized on a 2.5% agarose gel (Invitrogen, Carlsbad, Calif). EoE Tx, Trea-
ted EoE.
TABLE I. Clinical summary of children receiving ciclesonide as their primary treatment for EoE
Patients
1 2 3 4
Age (y) 4 4 16 7
Sex Male Male Female Male
Weight (kg) 12.7 18 49 24.5
Dose, total/d (mg) 320 640 320 320
Food allergy Y Y Y Y
Atopic history Y Y Y Y
Months of treatment September-November August-November August-October June-August
Dietary restriction Y Y Y Y
Pre/Post Pre/Post Pre/Post Pre/Post
Treatment:
Symptoms Slow growth/Weight gain Reflux, dysphagia, pain/None Dysphagia/None Vomiting, dysphagia/None
Endoscopic findings: Normal/Normal Normal/Normal Trachealization/Furrowing Furrowing/Furrowing
Histology
Proximal biopsy:
Eosinophil/hpf (340) 58/3 105/0 46/4 75/0
Basal zone hyperplasia Y/Y Y/N Y/N Y/Y
Rete peg elongation N/N Y/N Y/N Y/N
Spongiosis/edema Y/N Y/N N/N N/N
Degranulation Y/N N/N Y/N N/N
Microabscess N/N N/N N/N N/N
Distal biopsy:
Eosinophil/hpf (340) 75/0 100/0 30/3 100/0
Basal zone hyperplasia Y/Y Y/N Y/N Y/Y
Rete peg elongation Y/N Y/N Y/N Y/N
Spongiosis/edema N/N Y/N N/N N/N
Degranulation N/N N/N Y/N N/N
Microabscess N/N N/N N/N N/N
hpf, High-power field; N, no; Pre, before ciclesonide; Post, after ciclesonide; Y, yes.
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5,6 The formulation in a metered-dose in-
haler delivers a lipophilic particle (1.1-2.1 mm) that is subject
to high first-pass metabolism by the hepatic CY3PA4 system,
thus leading to low systemic bioavailability. Because of its low
systemic bioavailability, ciclesonide can potentially be used at
higher doses for EoE than other steroid preparations. All of these
features make ciclesonide an attractive therapeutic compound for
mucosal diseases, including EoE.
Other factors could have contributed to clinicopathologic
improvements, including improved adherence to this prescribed
drug, undocumented changes in diet, or change of season. In
addition, and deserving of more study, is the fact that the oral
bioavailability of oropharyngeal ciclesonide is low.7 Whether ep-
ithelial expression of esterases varies between esophageal and
oral epithelia is currently not known.Our results support our hypothesis that ciclesonide is another
topical steroid that might offer benefit in treating children with
EoE. Because this is a small case series report, we suggest caution
with ciclesonide use. Nonetheless, our findings provide prelim-
inary data to support further clinical and mechanistic studies of
ciclesonide in the treatment of EoE.
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